Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer

NCT04729608 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

366

Enrollment

INDUSTRY

Sponsor class

Stopped There were no significant differences in median PFS between batiraxcept + paclitaxel or paclitaxel alone arms. There was no detriment to overall survival. No new safety signals were identified.

Conditions

Platinum-resistant Ovarian Cancer

Interventions

DRUG: Batiraxcept
DRUG: Paclitaxel
OTHER: Placebo

Sponsor

Aravive, Inc.

Collaborators

[object Object]
[object Object]